Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen
Clinical trial NCT02822794 · COMPLETED
Trial details
- NCT number
- NCT02822794
- Sponsor
- Gilead Sciences
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-07-25
- Primary completion
- 2017-06-02
- Enrollment
- 117
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.